End-Stage Renal Disease (ESRD) is a major disease state, costing the U.S. $9.5 billion in 1992, and increasing 10% yearly. The growth in the number of ESRD patients can be attributed principally to demographic trends: the aging of the general population and the improved treatment and increased survival rate of patients with diabetes, hypertension, and other illnesses that lead to ESRD. Moreover, improved dialysis technology has enabled older patients and those who previously could not tolerate dialysis due to other illnesses to benefit from this treatment.
Three modalities exist for the treatment of ESRD: hemodialysis, peritoneal dialysis, and kidney transplant. This article reviews the medical treatments and the synthetic polymers used in the manufacture of vascular access grafts. We report on the development of a new, polyurethane-based microporous vascular graft, which displays self-sealing and improved compliance characteristics for use in vascular access grafting.
Get full access to this article
View all access options for this article.
References
1.
1. Brescia MJ, Cimino JE, Appel Ket al, Chronic haemodialysis using venepuncture and a surgically created arteriovenous fistula. N. Eng. J. Med, 275:1089-1092, 1996.
2.
2. Jenkins, A. McL., Buist, T.A.S., Glover, S.D., "Medium term follow-up of forty autogenous vein and forty PTFE (Goretex) grafts for vascular access,"Surgery, 88:667-672, (1979).
3.
3. Winsett, O.E., Wolma, F.J., "Complications of vascular access for hemodialysis,"South Med J78:513-517, (1985).
4.
4. Renal Data System. USRDS 1997 annual data report. Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases, 1997.
5.
5. Ad Hoc Committee on Nephrology Manpower Needs. Estimating workforce and training requirements for nephrologists through the year 2010. J. Am Soc Nephrol1997-8, Suppl 9:1-32.
6.
6. Winston JA, Klotman PE.Are we missing an epidemic of HIV-associated nephropathy?J Am Soc Nephrol1996; 7.1-7.
7.
7. D'Agati V, Appel GB. HIV infection and the kidney. J Am Soc Nephrol1997; 8:138-152.
8.
8. Pastan, S. and Bailey J., "Dialysis Therapy,"NEJM, 338:20, 1428-1437, 1998.
9.
9. Raju S: PTFE grafts for hemodialysis access. Techniques for insertion and management of complications. Ann Surg206:666-673, 1987.
10.
10. Bell DD, Rosental JJ: Arteriovenous graft life in chronic hemodialysis. A need for prolongation. Arch Surg123:1169-1172, 1988.
11.
11. Bone GE, Pomjzl MJ: Management of dialysis fistula thrombosis. Am J Surg138:901-906, 1979.
12.
12. Glanz, S, Bashist B, Gordon DH, et al: Angiography of upper extremity access fistulas for dialysis. Radiology143:4552, 1982.
13.
13. Schwab SJ, Raymond JR, Saeed M, et al: Prevention of hemodialysis fistula thrombosis. Early detection of venous stenoses. Kidney Int36:707-711, 1989.
14.
14. Gain JS, Fowler PR, Steinberg AW, et al: Use of the fistula assessment monitor to detect stenoses in access fistulae. Am J Kidney Dis17:303-306, 1991.
15.
15. Rittgers SE, Garcia-Valdez C, McCormick JT, Posner MP: Noninvasive flow measurement in expanded polytetrafluoroethylene grafts for hemodialysis access. J Vasc Surg3:635-642, 1986.
16.
16. Weber M, Kuhn FP, Quintes W, et al: Sonography of arteriovenous fistulae in hemodialysis patients. Clin Nephrol22:258-261, 1984.
17.
17. Gmelin E, Einterhoff R, Rinast E: Insufficient hemodialysis access fistulas: Late results in treatment with percutaneous balloon angioplasty. Radiology171:657-660, 1989.
18.
18. Zeit RM, Cope C: Failed hemodialysis shunts. One year of experience with aggressive treatment. Radiology154:353-356, 1985.
19.
19. Harter HR, Burch JW, Majerus PW, et al: Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med301:577-579, 1979.
20.
20. Flye MW, Mundinger GH, Schulz SC, et al: Successful creation of arteriovenous fistulas in nonuremic patients with heparin and aspirin therapy. Am J Surg142:759-673, 1981.
21.
21. Jacobs, C, Brunner SP, Chantler C, et al: Combined report on regular dialysis and transplantation in Europe. Proc Eur Dial Transplant Assoc14:3-69, 1977.
22.
22. Dobkin JF, Miller MH, Steigbigel NH: Septicemia in patients on chronic hemodialysis. Ann Intern Med88:28-33, 1978.
23.
23. Martin RR, Ekoyan G, Saenz C, et al: Effects of renal failure on leukotaxis. J Med10:267-278, 1979.
24.
24. Peresesuschi G, Blum M, Aviram A, Spirer ZH: Impaired neutrophil response to acute bacterial infection in dialyzed patients. Arch Intern Med141:1301-1302, 1981.
25.
25. Salant DJ, Glover AM, Anderson R, et al: Depressed neutrophil chemotaxis in patients with chronic renal failure on dialysis and after renal transplantation. J Lab Clin Med.88:536-545, 1976.
26.
26. Hanicki Z, Cichocki T, Komerowska Z, et al: Some aspects of cellular immunity in the construction of vascular access for hemodialysis. Nephron23:273-275, 1979.
27.
27. Hurst KS, Saldhana LF, Steinberg SM, et al: The effects of varying dialysis regimens on lymphocyte transformation. Trans Am Soc Artif Intern Organs21:329-334, 1975.
29. Kirmani N, Tuazon CU, Murry HW, et al: Staphylococcus aureus carriage rate of patients receiving long-term hemodialysis. Arch Intern Med138:1657-1659, 1978.
30.
30. Kaplowitz LG, Comstock JA, Landwehr DM, et al: Prospective study of microbial colonization of the nose and skin and infection of the vascular access site in hemodialysis patients. J Clin Microbiol26:1257-1262, 1988.
31.
31. Moore WS, Swanson RJ, Compagna G, et al: Pseudointimal development and vascular prosthesis susceptibility to bacteremic infection. Surg Forum25:250-251, 1974.
32.
32. Bennion RS, Wilson SE, Williams RA: Vascular prosthetic infection. Infect Surg1:45-55, 1982.
33.
33. Ehrenfield WK, Wilbur BG, Olcott CN, Stoney RJ: Autogenous tissue reconstruction in the management of infected prosthetic grafts. Surgery85:82-92, 1979.
34.
34. Kaiser AB, Clayson DR, Mulherin JL, et al: Antibiotic prophylaxis in vascular surgery. Ann Surg188:283-289, 1978.
35.
35. Pitt, HA, Postier RG, MacGowen WAL, et al: Prophylactic antibiotics in vascular surgery. Ann Surg192:356-364, 1980.
36.
36. Bennion RS, Hiatt JR, Williams RA, Wilson SE: A randomized, prospective study of perioperative antimicrobial prophylaxis for vascular access surgery. J. Cardiovasc Surg 26:270-274, 1985.
37.
37. Fivush BA, Bock GH, Guzzetta PC, et al: Vancomycin prevents polytetrafluoroethylene graft infections in pediatric patients receiving chronic hemodialysis. Am J Kidney Dis5:120-123, 1985.
38.
38. Goldblum SE, Reed WP.Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med1980;93:597-613.
39.
39. Ruiz P, Gomez F, Schreiber AD.Impaired function of macrophage Fcγ receptors in end-stage renal disease. N Engl J Med1990;322:717-722.
40.
40. Onyekachi, I., "Care of Patients Undergoing Hemodialysis,"NEJM, 339;15, 1054-1062, 1998.
41.
41. Pastan S, Bailey J. Dialysis therapy. N Engl J Med1998;338:1428-1437.
42.
42. Borah MF, Schoenfeld PY, Gotch FA, Sargent JA, Wolfsen M, Humphreys MH. Nitrogen balance during intermittent dialysis therapy of uremia. Kidney Int1978;14:491-500.
43.
43. Oh MS, Levison SP, Carroll HJ. Content and distribution of water and electrolytes in maintenance hemodialysis. Nephron1975;14:421-432.
44.
44. Boddy K, King PC, Lindsay R-M, Briggs JD, Winchester JF, Kennedy AC. Total body potassium in non-dialysed and dialysed patients with chronic renal failure. BMJ1972;1:771-775.
45.
45. Sandle GI, Gaiger E, Tapster S, Goodship TH. Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci1987;73:247-252.
46.
46. Linas SL. The role of potassium in the pathogenesis and treatment of hypertension. Kidney Int1991;39:771-786.
47.
47. Khaw K-T, Barrett-Connor E. Dietary potassium and stroke-associated mortality: a 12-year prospective population study. N. Engl J Med1987;316:235-240.
48.
48. Clausen T, Everts ME. Regulation of the Na,K-pump in skeletal muscle. Kidney Int1989;35:1-13.
49.
49. Ifudu O, Chan E, Brezsnyak WF, et al.Interdialytic weight gain and missed dialysis treatments in long-term hemodialysis patients. Dial Transplant1995;24:292-303.
50.
50. Gomez Farices MA, McClellan W, Soucie JM, Mitch WE. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J. Kidney Dis1994;23:3828.
51.
51. de Lemos JA, Hillis LD. Diagnosis and management of coronary artery disease in patients with end-stage renal disease on hemodialysis. J Am Soc Nephrol1996;7:2044-2054.
52.
52. Owen CH, Cummings RG, Sell TL, Schwab SJ, Jones RH, Glower DD. Coronary artery bypass grafting in patients with dialysis-dependent renal failure. Ann Thorac Surg1994;58:1729-1733.
53.
53. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzier GO. Short- and long-term outcome of percutaneous transluminal coronary angioplasty in chronic dialysis patients. Am Heart J1990;119:484-489.
54.
54. Schlessinger SD, Tankersley MR, Curtis JJ. Clinical documentation of end-stage renal disease due to hypertension. Am J Kidney Dis1994;23:655-660.
55.
55. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH. Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis1992;19:453-459.
56.
56. Charra B, Calemard E, Cuche M, Laurent G. Control of hypertension and prolonged survival on maintenance hemodialysis. Nephron1983:33:969.
57.
57. Ifudu O. The concept of "dry weight" in maintenance hemodialysis: flaws in clinical application. Int J Artif Organs1996;7:384-386.
58.
58. Lundin AP. Recurrent uremic pericarditis: a marker of inadequate dialysis. Semin Dial1990;3:5-6.
59.
59. Eschbach JW, Abdulhadi MH, Browne JK, et al.Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. Ann Intern Med1989;111:992-1000.
60.
60. McMahon LP, Dawborn JK. Experience with low dose intravenous and subcutaneous administration of recombinant human erythropoietin. Am J Nephrol1990;10:404-408.
61.
61. Fishbane S, Maesaka JK. Iron management in endstage renal disease. Am J Kidney Dis1997;29:319-333.
62.
62. Fairbanks VF, Beutler E. Iron deficiency. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams hematology. 5th ed.New York: McGraw-Hill, 1995:490-511.
63.
63. Beamish MR, Davies AG, Eakins JD, Jacobs A, Trevett D. The measurement of reticuloendothelial iron release using iron-dextran. Br J Haematol1971;21:617-622.
64.
64. Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron1978;22:347-353.
65.
65. Johnson G, Blythe WB: Hemodynamic effects of arteriovenous shunts used for hemodialysis. Ann Surg171:715-721, 1970.
66.
66. Jensen JA, Goodson WH, Omachi RS, et al: Subcutaneous tissue oxygenation falls during hemodialysis. Surgery101:416-421, 1987.
67.
67. Ahern DJ, Maher JF: Heart failure as a complication of hemodialysis arteriovenous fistula. Ann Intern Med77:201-204, 1972.
68.
68. Anderson CB, Codd JR, Graff RA, et al: Cardiac failure and upper extremity arteriovenous dialysis fistulas. Arch Intern Med136:292-297, 1976.
69.
69. Anderson CB, Etheridge EE, Harter HR, et al: Blood flow measurements in arteriovenous dialysis fistulas. Surgery81:459-461, 1977.
70.
70. Riley SM, Blackstone EH, Sterling WA, Diethelm AG: Echocardiographic assessment of cardiac performance in patients with arteriovenous fistulas. Surg Gynecol Obstet146:203-208, 1978.
71.
71. Von Bibra H, Castro L, Autenieth G, et al: The effects of arteriovenous shunts on cardiac function in renal dialysis patients: An echocardiographic evaluation. Clin Nephrol9:205-209, 1978.
72.
72. Storey BG, George CRP, Stewart JOH, et al: Embolic and ischemic complications after anastomosis of radial artery to cephalic vein. Surgery66:325-327, 1969.
73.
73. Bussell JA, Abbott JA, Lim RC: A radial steal syndrome with arteriovenous fistula for hemodialysis. Ann Intern Med.75:387-394, 1971.
75. Duncan H, Ferguson L, Faris I: Incidence of the radial steal syndrome in patients with brescia fistula for hemodialysis: Its clinical significance. J. Vasc Surg4:144-147, 1986.
76.
76. Odland MD, Kelly PH, Ney AL, et al: Management of dialysis-associated steal syndrome complicating upper extremity arteriovenous fistulas: Use of intraoperative digital photoplethysmography. Surgery110:664-670, 1991.
77.
77. Drury, JKet al., "Experimental and clinical experience with a gelatin impregnated Dacron prosthesis,"Ann. Vasc. Surg., 5:542-547, (1987).
78.
78. Anderson, JM, "The pathology and healing responses of ePTFE vascular access grafts," Wilson, S.E., Vascular Access Surgery, 2nd ed., Chicago: Year Book Medical Publishers, (1988).
79.
79. Abbott W. and Cambria RPIn: Biologic and Synthetic Vascular Prostheses. Grune and Stratton, 1982, 189-220.
80.
80. K. Hayaski, "Mechanical properties of biomaterials: Relationship to clinical applications," in Contemporary Biomaterials: Material and Host Response, Clinical Applications, Neu, Technology and Legal Aspects, J. W. Boretos and M. Eden (eds.), Noyes, Park Ridge, NJ, 1984, pp. 46-65.
81.
81. R. F. Rushmer, Medical Engineering, Academic Press, New York, 1972.
82.
82. Y. C. Fung, Biomechanics—Mechanical Properties of Living Tissues, Springer-Verlag, New York, 1981.
83.
83. P. E. Paasche, C. E. Mnley, F. G. Dolan, E. R. Gozna, and A. E. Marble, "Consideration of suture line stresses in the selection of synthetic grafts for implantation,"1. Biomechanics, 6, 253-259 (1973).
84.
84. C. E. Kinley and A. E. Marble, "Compliance: A continuing problem with vascular grafts,"J. Cardiovasc. Surg., 21, 163-170 (1980).
85.
85. J. A. De Weese, "Anastomotic intimal hyperplasia," in Vascular Grafts by P. N. Sawyer and M. J. Kaplitt (eds.), Appleton-Century-Crofts, New York, 1978, pp. 147-152.
86.
86. D. N. Ghista and T. Moskal, "Biomechanical estimate for optimal coronary bypass graft diameter for maximal coronary perfusion,"1983 Biomechanics Symposium by S. L.-Y. Woo and R. E. Mates (eds.), Am. Soc. Mech. Eng., New York, 1983, pp. 181-183.
87.
87. G. Kidson and W. M. Abbott, "Low compliance and arterial graft occlusion,"Circulation, 58 (Suppl. 1), II-14 (1978).
88.
88. R. Walden, G. J. L'Italien, J. Megerman, and W. M. Abbott, "Matched elastic properties and successful arterial grafting,"Arch. Surg., 115, 1166-1169 (1980).
89.
89. D. J. Lyman, E. C. Lyman, and E. Eichwald, "The effect of graft compliance on the patency of small-diameter polyurethane vascular grafts,"Trans. 3rd World Biomat. Cong. (Kyoto, Apr. 21-25, 1988), (1988), p. 55.
90.
90. D. Annis, T. V. How, and A. C. Fisher, "Recent advances in the development of artificial devices to replace diseased arteries in man: A new elastomeric synthetic artery graft," in Polyurethanes in Biomedical Engineering, H. Planck, G. Egbers, and I. Syré (eds.), Elsevier Sci. Pub., Amsterdam, 1984, pp. 287-300.
91.
91. T. V. How and R. M. Clarke, "The elastic properties of a polyurethane arterial prosthesis,"J. Biomechanics, 17, 597-608 (1984).
93. Kowligi R.R., Calcotte, R.W., "Vascular prostheses from polyurethanes: Methods for fabrication and evaluation,"High Performance Biomaterials., edit Szycher M.Technomic Publishing Co., Inc., ISBN 877-775-4 1991.
94.
94. Reed, A.M., "A Solution Grade Biostable Polyurethane Elastomer, ChronoFlex AR,"J. Biomat.App., Vol 8, Jan 1994.
95.
95. Biostable polyurethane products., USA Patent: 5,254,662.
96.
96. Anderson, J.A.1988. Inflammatory response to implants. ASAIO, II(2): 101-107.
97.
97. Stokes, K.1988. Polyether polyurethanes: Biostable or not?Biomater Appl3:228-259.
98.
98. Anderson, J.1993. Mechanisms of Inflammation and Infection With Implanted Devices. Cardiovasc Pathol2(3 Suppl);33S-41S.
99.
99. Sibille, Y. and Reynolds, H.V.1990. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis, 141:471-501.
100.
100. Angeline, B.D., Hiltner, A and Anderson, J.M.1990. Long term in vitro enzymatic biodegradation of Pellethane 2363-80A: A mechanical study. In Barenberg, S.A., Brash, J.L, Narayan, R. and Redpath, A.E. (eds), Degradable Materials: Perspectives, Issues and Opportunities, Boca Raton, CRC Press, pp. 295-322.
101.
101. Szycher, M., "Surface fissuring of polyurethanes following in vivo exposure," ASTM, STP 859, 308-321, Fraker and Griffin, eds., Philadelphia.
102.
102. Williams, D.J., J. Bioeng., 1279-1294 (1977).
103.
103. Phua, S.K., and Anderson, J.M., "Biodegradation of a polyurethane in vitro,"J. Biomed. Mat. Res., 21, 231-246, 1987.
104.
104. Wasserbauer, R., Beranova, M., Vancurova, D.,et al.1990. Biodegradation of polyethylene foils by bacterial and liver homogenates. Biomaterials, 11(1):36-40.
105.
105. Stokes, K., Urbanski, P., and Cobian, K.1987. New test methods for the evaluation of stress cracking and metal catalyzed oxidation in implanted polymers. In Polyurethanes in Biomedical Engineering II, H. Planck, et al (eds.), Elsevier, Amsterdam, pp. 109-128.
106.
106. Wu, Y.K., Lodoen, G.A., Anderson, J.M., Baer, E. and Hiltner, A.1994. Creep of a poly(etherurethane urea) in an oxidative environment. J Biomed Mater Res, 28; 515-522.
107.
107. Stokes, M., R. McVenes and J.M. Anderson. "Polyurethane elastomer biostability,"J. Biomat. Appl., 9:321-354 (1995).
108.
108. Stokes, K., Frazer, W.A., and Carter, E.A.1984. The biostability of various polyether polyurethanes under stress. ANTEC'84, 1073-1075.
109.
109. Smith, R., Williams, D.F., Oliver, C.1987. The biodegradation of poly(ether)urethanes. J. Biomed Mater Res, 21:1149-1166.
110.
110. Wu, Y.K., Lodoen, G.A., Anderson, J.M., Baer, E. and Hiltner, A.1994. Creep of a poly(etherurethane urea) in an oxidative environment. J Biomed Mater Res, 28; 515-522.
111.
111. Zhao, Q., Casas-Bejar, J., Urbanski, P., and Stokes, K., "The glass wool H2O2/CoCl2, Test system for in vitro evaluation of biodegradative stress cracking in polyurethane elastomers,"J. Biomed. Mater. Res., 29:467-475, 1995.
112.
112. Methods and Apparatus for Making a Polymer Material. Euro Patent: 0286220. U.S.A. Patent: 5132066. Japanese Patent: 63-78318.
113.
113. Carson, R.J., "Resistance to Biodegradative Stress Cracking in Microporous Vascular Graft,"Int Soc Applied Cardiovascular Biology. Fifth meeting Manchester, March 1996.
114.
114. Carson R.J., "Resistance to Biodegradative Stress Cracking in Microporous Vascular Access Grafts,"J. Biomat. App., 11:121-134, Oct 1996.
116. Voorhees, A.B., Jaretzi, A. and Blackmore, A.H., "The use of tubes of Vinyon N cloth in bridging arterial defects,"Ann. Surg.135:332, 1952.
117.
117. Clowes, A.W., Kirkman, T.R., and Reidy, M.A., "Mechanisms of porosity in arterial prosthesis,"Am. J. Pathol., 123:220-230, (1986).
118.
118. Fry, W.J., DeWeese, M.S., Carft, R.O., and Ernst, C.B., "Importance of porosity in arterial prosthesis,"Arch Surg.88:836-842, (1954).
119.
119. Windus, D.W., "Permanent vascular access: A nephrologists view,"Am. J. Kidn. Dis., Vol 21, No 5, May 1993.
120.
120. Hodges, T.C., Fillinger, M.F., Zwolak, R.M.,et al., Longitudinal comparison of dialysis access methods: Risk factors for failure. J Vasc Surg. Vol 26 No 61997.
121.
121. Delorme, J.M., et al"Vascular access for haemodialysis: Pathological features of surgically excised ePTFE grafts,"Ann. Vasc. Surg. Vol 6, No 61992.
122.
122. Edwards, A., Carson, R.C., "Development of a Microporous Compliant Small Diameter Vascular Graft,"Int Soc Applied Cardiovascular Biology. Fifth meeting, Manchester, March 1996.
123.
123. Edwards, A., Carson, R.C., "Development of a Microporous Vascular Access Graft with `Self Sealing' Properties,"Angioaccess for Hemodialysis. Tours, June 1996, Edit, Bourquelot, P.
124.
124. W. L. Gore, Techniques for the care and cannulation of A-V Fistulas, 1988.
125.
125. Tordoir, J.H.M., Hofstra, L., Leunissen, M.K., et al., Early experience with stretch PTFE grafts for haemodialysis access surgery: of a prospective randomised study. Eur J Vasc Endovasc Surg.9, 305-309, 1995.
